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Amyloidosis refers to a group of protein misfolding diseases characterized by deposition of a particular amyloid protein in
various organs and tissues of animals and humans. Various types and clinical forms of amyloidosis, in which the pathology and
pathogenesis is diverse depending upon the underlying causes and species aﬀected, are reported in domestic and wild animals. The
clinical ﬁndings are also quite variable consequent to the variation of the tissues and organs involved and the extent of functional
disruption of the aﬀected organs in various animal species. The aﬀected organs may be enlarged and exhibit variable pallor grossly,
or the amyloid deposit may be discernible only after microscopic examination of the aﬀected tissues. Amyloid appears as a pale
eosinophilic homogenous extracellular deposit in tissues. However, microscopic examination and Congo red staining with green
birefringence under polarized light are needed to conﬁrm amyloid and diﬀerentiate it from other apparently similar extracellular
deposits such as collagen and ﬁbrin. Identifying the type of amyloid deposit needs immunohistochemical staining, ultrastructural
characterizationoftheamyloidﬁbril,andiffeasiblealsogeneticstudiesoftheinvolvedspeciesforclinicalandprognosticpurposes.
This paper provides a concise review of the occurrence of amyloidosis in domestic and wild animals.
1.Introduction
Amyloid is a pathologic proteinaceous substance deposited
between cells in various tissues and organs of the body in
a wide variety of clinical settings [1]. Although there are
othercomponentspresentinthedeposit,theamyloidprotein
ﬁbril is the main component of the amyloid substance. The
deposit diﬀers in protein composition depending upon the
types of amyloidosis and the diﬀerent clinical forms. Each
clinical entity of amyloidosis may be manifested by a distinct
clinical form with chemically speciﬁc amyloid ﬁbril protein.
This indicates that amyloid is a biochemically heterogeneous
substance, although there are similarities in properties and
staining characteristics.
1.1. Nomenclature and Classiﬁcation of Amyloidosis. Accord-
ing to the WHO-IUIS Nomenclature Subcommittee [2]
on the nomenclature of amyloid and amyloidosis, amy-
loid and amyloidosis are classiﬁed based on the amyloid
ﬁbril protein, followed by a designation of the ﬁbril
protein precursor. The capital letter A for amyloid is
followed by the protein designation in abbreviated form.
For example AL-amyloid refers to the amyloid derived from
immunoglobulin light chain and may be seen in amyloidosis
including idiopathic (primary) amyloidosis associated with
myeloma or macroglobulinaemia [2]. The origin of the
ﬁbril in AL-amyloidosis is an immunoglobulin light chain
or immunoglobulin heavy chain fragment [3]. The amyloid
ﬁbril protein in the immunoglobulin heavy chain has been
given the designation AH [2]. AA-amyloid refers to the
amyloid derived from serum A-amyloid protein (SAA), with
apoSAA as its precursor protein. AA-amyloid is deposited
in tissues as reactive (secondary) amyloidosis and familial
amyloidosis.Furthermore,amyloiddepositisclassiﬁedbased
on various precursor proteins identiﬁed in diﬀerent types
and forms of amyloidosis. For example Aβ and β protein
precursor (βPP) are respectively identiﬁed as the amyloid
ﬁbril protein and its precursor in Alzheimer’s disease. Islet
amyloid polypeptide is a precursor for AIAPP amyloid
protein deposited in pancreatic amyloidosis. Familial amy-
loidosis in humans could be due to mutations in ﬁbrinogen,2 Veterinary Medicine International
lysozyme, apolipoprotein AI, and transthyretin (with ATTR
as amyloid protein). Human hereditary systemic amyloidosis
with renal involvement, which is clinically indistinguishable
from AL-amyloid deposit, is reported to have deposition of
apolipoprotein AI (apoAI) or AII, lysozyme, or ﬁbrinogen.
Deposition of native transthyretin is also associated with
senile systemic amyloidosis in elderly patients [2, 3].
Diﬀerent types and clinical forms of amyloidosis are
known based on the deposition in tissues and organs of
various domestic and wild animals. Amyloidosis involving
several tissues and organs throughout the body is referred
to as systemic amyloidosis. Systemic amyloid deposition
can be due to AL-amyloidosis, AA-amyloidosis, or familial
amyloidosis. Amyloid substance may be conﬁned at a given
areainthebodyintheformoflocalizedamyloidosis.Various
forms of local amyloid deposits are known in animals
and humans. This includes deposition of Aβ protein in
Alzheimer’s disease, AIAPP in pancreatic islet, AANF in
atrial amyloid deposit with βPP, islet amyloid polypeptide,
and atrial natriuretic factor as their respective precursors
(Table 1)[ 2]. The pathogenesis, pathology, and clinical
presentations of amyloidosis are protean consequent to the
diverse underlying causes of its various forms, species of
animals aﬀected, and the severity of functional disruption
in diﬀerent tissues and organs involved. The diagnosis
of amyloidosis requires histopathologic identiﬁcation of
amyloid deposits in the aﬀected tissues. This is conﬁrmed by
Congo red staining and green birefringence under polarized
light.
This paper provides a concise review of amyloidosis and
its associated factors and clinical syndromes encompassing
various forms of amyloidosis in domestic and wild animals
and would be of importance as a reference for veterinary
professionals and students.
2. Pathology and Pathogenesis
The pathology and pathogenesis of amyloidosis is extremely
variable due to the multifarious underlying causes of its
various forms in diﬀerent species of animals. About 20–
25 diﬀerent types of proteins with the ability to aggregate,
insolubilize, and deposit in tissue as amyloid have been
identiﬁed [4, 5]. A review of the pathology underlying
various protein foldings in domestic animals including
amyloidosis is given by Gruys [5]. In animals, at least eight
diﬀerent amyloid precursors have been described [6]. The
precursor proteins in amyloid ﬁbrils may be amyloidogenic
mutants as in some familial amyloidosis, whereas other
precursors are normal wild-type proteins [5, 7]. The exact
mechanisms through which the proteins are converted into
amyloid ﬁbrils in vivo are not well known [7].
The pathogenesis of amyloid deposition in AA- and
AL-amyloidosis diﬀers in character [8]. Amyloid results
from abnormal folding of proteins which are deposited as
ﬁbrils in extracellular tissues and disrupt normal function.
Misfolded proteins are often unstable and self-associate,
ultimately leading to the formation of oligomers and ﬁb-
rils deposited in tissues. Normally, misfolded proteins are
degraded intracellularly in proteasomes or extracellularly
by macrophages, which in amyloidosis fail to occur [1]. In
AL-amyloidosis unstable monoclonal immunoglobulin light
chains, produced by a plasma cell dyscrasia, lead to the
formation and deposition of ﬁbrils [9]. In AA-amyloidosis,
there is increased level of SAA, which is common in the
inﬂammatorystates.However,increasedSAAisnotsuﬃcient
for the deposition of amyloid leading to amyloidosis. The
SAA deposition in AA-amyloidosis would be due to defect
in the degrading monocyte-derived enzymes or genetically
determined structural abnormality in SAA molecule [1].
Although acute phase SAA is mainly synthesized by hep-
atocytes, extrahepatic SAA expression and production is
reported in several species of animals and humans [10]. For
e x a m p l ei nm i c eS A Am R N A sw e r ef o u n dt ob ee x p r e s s e d
in the heart, kidney, lung, intestine, spleen, and peritoneal
macrophages[11].Adeﬁniteroleforextrahepaticallyformed
SAA is still unclear. However, there is some evidence linking
theextrahepaticSAAproductiontoamyloiddeposition,such
as in a rat synapsin I-Sa a1 (SYNI) transgenic mouse model
[12] and in the brown chicken joint after intra-articular
injection with various agents [13].
Otherfactorsandproductsincludingamyloid-enhancing
factor (AEF), the isoform or proteolytic cleavage site of
SAA, and glycosaminoglycans (GAGs) are involved in the
development of amyloidogenesis [10]. The AEF, prepared
from AA laden mouse liver consisting of proteins that
are chemically identical to the AA molecule, was capable
of accelerating amyloidosis even in femtomolar doses and
retained its biologic activity over a considerable period [14].
A single amyloidogenic protein may result in multiple
forms of amyloid ﬁbrils depending on their induction
conditions, and multiple mechanisms for amyloidogenesis
are expected to operate as witnessed with their ﬁbrillar
polymorphism [15]. Although there are divers proteins
associated with the formation of amyloid, they are all
characterized by misfolded proteins which result in self-
associated and unstable ﬁbrils [16]. Protein ﬁbril is the main
component of the amyloid substance; however, there are
other components present, the importance of which is yet
not well established in the pathogenesis of amyloidosis. All
formsofamyloidcontainthepentraxinglycoproteinamyloid
P-component (AP) that most probably is bound to the
protein ﬁbrils directly. The unique β-sheet ﬁbril of amyloid
is very resistant to physical agents and also gives the amyloid
substance many of its characteristic properties, including
aﬃnity to the dye Congo red and green birefringence under
polarized light after such staining [7].
3. AA-Amyloidosis inAnimals
AA-amyloidosis is the most common form of amyloidosis in
domestic animals. It is associated with chronic inﬂammatory
or neoplastic diseases (nonimmunocyte dyscrasia), or it may
be idiopathic, where no underlying disease is found [16, 17].
In this form of amyloidosis, the deposited amyloid A is
derived from the acute phase reactant, serum amyloid-A
(SAA) [5, 17, 18], which is an apolipoprotein of high-densityVeterinary Medicine International 3
Table 1: Nomenclature and classiﬁcation of amyloid and amyloidosis. Source: WHO/IUIS Nomenclature subcommittee [2].
Amyloid
proteina,b Protein precursor Protein type Clinical diagnosis
AA apoSAA
Reactive (secondary) amyloidosis, familial mediterranean
fever, familial amyloid nephropathy with urticarial and
deafness (Muckie-Wells’ syndrome)
AL κλ, for example, κIII Aκ,A λ, for example,
AκIII
Idiopathic (primary) amyloidosis associated with
myeloma/macroglobulinaemia
AH IgG1 (γ1)A γ1
ATTR Transthyretin
For example, Met 30c
For example, Met III
TTR or IIe 122
Familial amyloid polyneuropathy, Portuguese
Familial amyloid cardiomyopathy, Danish
Systemic senile amyloidosis
AApoAI apoAI Arg 26 Familial amyloid polyneuropathy, Iowa
AGel Gelsolin Asn 187d (15) Familial amyloidosis, Finish
ACys Cystatin C Gin 68 Hereditary cerebral hemorrhage with amyloidosis, Icelandic
Aβ β protein precursor for
example, βPP 695e Gin 618 (22) Alzheimer’s disease, Down syndrome, and hereditary
cerebral hemorrhage with amyloidosis, Dutch
Aβ 2M β2-microglobulin Associated with chronic dialysis
AScr Scrapie protein precursor
33–35f cellular form
Scrapie protein 27–30 Creutzfeldt-Jakob disease, and so forth
For example, Leu 102 Gerstmann-Stra¨ ussler-Scheinker syndrome
ACal (Pro)calcitonin (Pro)calcitonin In medullary carcinomas of the thyroid
AANF Atrial natriuretic factor Isolated atrial amyloid
AIAPP Islet amyloid polypeptide In islets of Langerhans, diabetes type II, insulinoma
AInsg Insulin Islet amyloid in the degu (a rodent)
AApoAIIg apoAII (murine) Gin5 Amyloidosis in senescence, accelerated mice
aNonﬁbrillar proteins, for example, protein AP (amyloid P-component) excluded.
bAA: amyloid A protein; SAA: serum amyloid A protein; apo: apolipoprotein; L: immunoglobulin light chain; H: immunoglobulin heavy chain.
cATTR Met 30 when used in text.
dAmino acid position in the mature precursor protein. The position in the amyloid ﬁbril protein is given in parentheses.
eNumber of amino acid residues; fMolecular mass (kilodaltons); gNot found in humans.
lipoproteins (HDL), classes 2 and 3. It is formed mainly in
the liver upon stimulation by proinﬂammatory cytokines [5]
and normally plays a role in cholesterol transport [18]a n d
as a chemoattractant [19] in the inﬂammatory processes.
When the concentration of this molecule is increased,
typicallyasaresultofchronicinﬂammation,certainisoforms
of SAA are partially cleaved into fragments that have an
increased propensity to form ﬁbrillar aggregates of amyloid
deposited systemically, mainly in the kidney, liver, and spleen
[20]. In systemic AA-amyloidosis, macrophages are activated
and elaborate endogenous pyrogens IL-1 and IL-6, which
stimulate hepatocytes to synthesize and secrete SAA. During
an inﬂammatory reaction, SAA in the serum may increase
several 100 times normal concentrations. However, not all
systemic inﬂammatory reactions lead to the formation of
AA-amyloid, but only some of the inﬂammatory reactions
lead to amyloidosis. Deposition of insoluble amyloid ﬁbrils
occurs either due to defect in SAA-degrading enzyme in the
system, or consequent to the synthesis of abnormal SAA
protein resistant to the enzymatic degradation [1, 16].
AA-amyloidosis is the most common type of amyloidosis
in mammals and birds and often results in hepatic or renal
failure due to physical disruption of the normal cellular
and organ processes [21]. It is a common disease of water
fowl and is characterized by the deposition of extracellular
ﬁbrils of amyloid-A protein in the liver and certain other
organs in this species [22]. AA-amyloidosis is also reported
in a wide variety of domestic animal species including
canines, equines, bovines, avian species, porcines, felines,
sheep,andgoats[6,23–30].Itisdescribedinassociationwith
diﬀerent chronic diseases in captive cheetah (Acinonyx juba-
tus), Siberian tigers (Panthera tigris altaica), mink (Mustela
vison), black-footed cats (Felis nigripes), black-footed ferrets
(Mustela nigripes), Dorcas gazelle (Gazella dorcas), mountain
gazelle(Gazella gazella), bighorn and Dall’s sheep, free-living
lioness, and in swans and other anatidae (Panthera leo)
[21, 31–41]. In the cheetahs, it is reported in association with
chronic lymphoplasmacytic gastritis and as idiopathic in the
Siberian tigers. In the cheetahs and the Siberian tigers, the
deposits were primarily in the medullary interstitium, with
minimal glomerular involvement [38, 39]. Deposition of the
amyloid in renal amyloidosis reported in the Dorcas gazelle
was also mainly in the renal medulla, sparing the glomeruli
[35].
3.1. Familial Forms of AA-Amyloid Deposit in Animals.
Familial amyloidosis refers to the deposition of amyloid
p r o t e i ni nt i s s u e so fa n i m a l si nag i v e ng e n e t i c a l l ya s s o c i a t e d
family prone to the deposition of amyloid ﬁbrils. Some
species of animals appear to have genetic predisposition to4 Veterinary Medicine International
the deposition of AA-amyloidosis. In veterinary medicine,
a few animal species are reported to be genetically prone
to deposition of amyloid in various tissues. Familial amy-
loidosis is reported in Siamese and Abyssinian cats and
Shar Pei dogs with the AA-proteins diﬀering in primary
sequences and patterns of deposition [23, 42, 43]. The
kidney is the main target organ for the deposition of
amyloid in the Abyssinian cat and Shar Pei dogs, while
the amyloid protein is mainly deposited in the liver in
Siamese cats [23, 43, 44]. Furthermore, analysis of SAA
cDNA sequences from several animals identiﬁed a distinct
geneticdimorphismthatmayberelevanttothesusceptibility
to secondary amyloid disease. The duck genome contained a
single copy of the SAA gene that was expressed in the liver
and lungs of ducklings, even in the absence of induction of
acute phase response [22]. Amyloid-resistant mouse strains
were found to have a non-amyloidogenic acute phase SAA
[45, 46], and rats were shown not to form acute phase
SAA and AA-amyloid at all [47, 48]. Additionally, there are
other animal species that appear to be prone to amyloid
deposition. The high prevalence of amyloidosis in captive
cheetahs is suggested to indicate some level of familial
predisposition similar to the Abyssinian cats [38]. Amyloid
arthropathyfrequentlyoccurredinbrownlayerchickens,but
never in white layers. The suspected higher susceptibility
of brown layers was conﬁrmed experimentally by inducing
amyloidosis with an arthropathic and amyloidogenic strain
of E. faecalis [49]. In the systemic amyloidosis reported
in the black-footed cats, there was no association with
concurrentchronic inﬂammatoryconditions, indicating that
the amyloid deposit was not secondary to inﬂammation.
Small amounts of amyloid deposition were also detected in
tissues from a single free-ranging black-footed cat indicating
a predilection for amyloidosis in these cats. Moreover, heri-
tability estimation also suggested that amyloidosis might be
familialinthisspecies[21].Therefore,inadditiontoSiamese
and Abyssinian cats and Shar Pei dogs, in which familial
amyloidosisiswellrecognizedinveterinarymedicine,certain
species such as captive cheetahs, Dorcas gazelles, black-
footed cat, and brown layer chickens appear to be genetically
predisposed to amyloidosis.
4. AL-Amyloidosis inAnimals
AL-amyloidosis is very rare in domestic animals [17], unlike
in humans, in which it is a common form of systemic
amyloidosis. Report on systemic AL-amyloidosis in domestic
animals is very rare. It is reported in a horse gelding with
multiple myeloma [17], a mare [50] ,a n di nac o ww i t h
bovine leukocyte adhesion deﬁciency [51]. Local deposition
of AL-amyloid is reported in various species of animals.
This includes diﬀuse to nodular, tracheal, and bronchial
AL-amyloidosis in dogs [52, 53] and cutaneous nodular
amyloidosis in equines [54]. Recently, non-AA-amyloid is
reported in two felines with thymomas [55]. AL-amyloid
deposition was reported in cats and dogs in association
with diﬀuse and local extramedullary plasmacytomas [56].
In animals, the deposition of AL-amyloid protein is gener-
ated following overproduction of monoclonal light chains
associated with immunocyte dyscrasia. In this form of
amyloidosis, plasma cells produce excessive quantities of
immunoglobulin light chains that are resistant to com-
plete enzymatic degradation and are susceptible to forming
insoluble ﬁbrils. The most common immunocyte dyscrasia
associated with AL-amyloidosis in domestic animals is a
neoplasm of plasma cell. The AL form of amyloid can
contain complete immunoglobulin light chains, the NH2-
terminus portion of immunoglobulin light chains, or both.
Immunoglobulin secreting cells, B lymphocytes, and plasma
cells are associated with the deposition of AL-amyloid [16].
In humans, the AL-amyloid type derived from immuno-
globulin light chains is the most common form of systemic
amyloidosis [57]. Small-sized bone marrow plasma cell
clones are reported to produce toxic light chains that cause
ﬁbrillar deposits in multiple organs [58]. The amyloid ﬁbrils
are formed by the N-terminal fragment of a monoclonal
immunoglobulin light chain comprising the variable region
andaportionoftheconstantregion.Onlyasmallproportion
of free monoclonal light chains form amyloid ﬁbrils in
vivo. Thus, the ability to form amyloid is probably related
to individual structural characteristics of the light chain
variable region. Unlike most other plasma cell dyscrasias,
the λ light chain isotype is prevalent in AL (κ/λ ratio,
1:3),suggestingtheexistenceofamyloid-associatedVλgerm
line genes [58]. In contrast to amyloidosis in humans, in
which the majority of patients with AL do not have any
overt B lymphocyte or plasma cell neoplasm, but do have
monoclonal antibodies or light chains in their serum or
urine, domestic species rarely have AL-type amyloid without
evidence of an immune dyscrasia [16].
5. Localized and Other Forms of
Amyloidosis in Animals
Localized amyloidosis refers to the deposition of amyloid
ﬁbrillar protein as a grossly visible mass or a microscopic
deposit at a given site in an organ or tissue. Localized AL-
amyloidosis is characterized by limited growth of mono-
clonal plasma cells and restriction of amyloid deposits to
sites adjacent to those of the synthesis of the precursor
[58]. Localized amyloidosis is reported in several animal
species involving diﬀerent tissues and organs. It is present in
calcifyingepithelialodontogenictumors(amyloidproducing
odontogenic tumors) of the cat and dog and pancreatic
islets in cats [5, 16]. Aβ-amyloid and APrPsc-amyloid
can be encountered in the brains of old dogs and sheep
with scrapie, respectively [5, 59]. Some forms of naturally
occurring transmissible spongiform encephalopathies such
as chronic wasting diseases (CWD) are characterized by
amyloid plaques in the brain in addition to the intraneural
vacuolation [16]. Deposition of amyloid derived from islet
amyloid polypeptide (IAPP), a normal protein secreted by
the β cell of the pancreas, is reported in the pancreas of cats
and macaques. The mechanisms by which IAPP undergoes
assembly and transformation into deposits of amyloid ﬁbrilsVeterinary Medicine International 5
are not fully understood [60, 61]. However, the islet amyloid
deposits in humans and feline and macaque animal models
of type 2 diabetes mellitus are associated with signiﬁcant
loss of islet β cells [61]. It is not known if the deposition
of amyloid and the development of clinical diabetes mellitus
is the result of progressive loss of β cells from the amyloid
deposit or if the deposition of the amyloid occurs as a result
of prolonged stimulation of the β c e l l sa sac o n s e q u e n c eo f
insulin resistance [16].
In horses, localized AL-amyloidosis is described in the
skin as cutaneous amyloidosis associated with lymphoma
[62] and extramedullary plasmacytoma [63]. Hepatic AA-
amyloidosis is commonly reported in serum-producing
horses [64].
In dogs, cutaneous amyloidosis can occur as primary
localized form or secondary to systemic amyloidosis. Most
cutaneous amyloidoses in dogs are suggested to be of
immunoglobulin light chain (AL) in type [65–67]a n da r e
reported in association with localized plasma cell prolifer-
ation, plasma cell dyscrasia, or cutaneous extramedullary
plasmacytoma [65, 68, 69]. As part of primary systemic
disease, diﬀuse, ﬁnely distributed cutaneous deposition is
reported in dogs with monoclonal gammopathy [66, 67,
69]a n dd e r m a t o m y o s i t i s[ 69]. However, primary localized
cutaneous form, which is rare in dogs [65, 66, 69], shows
solitary or rarely group of nodules in the subcutis and
dermis. The ears are most commonly involved [66, 67]
although lesions would be seen at any site on the body [66].
Similar to human senile amyloidosis, old dogs develop
neurodegenerative brain changes including cerebrovascular
amyloidosis and senile plaques with amyloid deposition. The
amyloid protein in the canine cerebrovascular amyloidosis is
deposited in the medium- and small-caliber arterioles and
capillaries of the leptomeninges and the brain parenchyma.
Vascular or perivascular degeneration or cellular reactions
were not detected in aﬀected vessels [70]. Such amyloid
deposits in the brain consist of a number of extracellular
proteins, but most commonly contain Aβ type amyloid,
whichconsistsofaproteolyticfragmentoftheAPP(Amyloid
Precursor Protein). The Aβ form of amyloid is associated
with the cerebral amyloid angiopathy of Alzheimer’s disease
in humans and with neurodegeneration in the canine
brain [16]. In the brain tissue of aged dogs, Alzheimer-
like pathology with lipofuscin being present in neurons
and macrophages, Aβ-precursor protein in neurons, Aβ-
positive plaques, and 4-hydroxynonenal in neurons and
macrophages, and limited intraneuronal accumulation of
tau and advanced glycation end products increasing with
longevity, has been encountered [71–74]. The amyloidosis
which causes neurodegenerative disorders is almost always
related to the intracerebral production of the pathogenic
protein since most proteins, like immunoglobulins, do not
cross the blood brain-barrier. One exception may be the case
of systemic amyloidosis related to transthyretin mutations,
which produce peripheral neuropathy and cerebral changes
in the white matter in some cases [75] and hematogenic
pattern of vascular deposition following systemic amyloido-
sis in areas of the brain that lack tight blood-brain barrier
such as small circumventricular areas around the third and
fourth ventricles, the infundibulum, and area postrema
[76]. Aβ-amyloid in the brain tissue of aged dogs, showing
signs of dementia, forms a canine counterpart of senile
dementia of the Alzheimer type (ccSDAT) in man. Other
organ systems containing amyloid in the aged dog are the
heart, gastrointestinal tract, and lungs. The deposition of
amyloid in the pulmonary vasculature of the aged dogs
was reported to be derived from apolipoprotein AI (Apo
AI) [16]. Severe senile amyloidosis is also reported to be a
characteristic of age-associated disorder in the SAMP1 and
SAMP10 strains of mice, making them a valuable model to
investigate pathogenesis of amyloidosis and to assist in the
development of eﬀective therapeutic modalities [77].
6.ClinicalFindings
Amyloidosis is a feature of several diﬀerent pathologic
mechanisms and as such should not be considered a single
disease, but rather a group of diseases having in common
the deposition of similar appearing proteins [16]. Animals
aﬀected with amyloidosis may show variable clinical signs
duetovariationinthemainunderlyingdiseaseascommonly
seen in AA-amyloidosis or those solely attributable to the
deposition of amyloid in a given tissue or both. Some
local amyloid depositions may be clinically nonsigniﬁcant
incidental ﬁndings in certain tissues. In most cases, small
local amyloid masses pose no clinical problems. Therefore,
the clinical ﬁnding of amyloidosis in aﬀected animals is
variable and reﬂects the extent of perturbed function of
the predominantly aﬀected organs and tissues due to the
depositionofamyloidormayshowvariableclinicalsignsthat
may be associated with the underlying chronic disease and
the concurrent amyloid deposit. For example, kidney is the
main target organ for the deposition of amyloid in familial
amyloidosis of the Abyssinian cat (glomerular deposit) and
Shar Pei dogs (medullary deposit), while the amyloid is
mainlydepositedintheliverinSiamesecats[23,44].Because
amyloid deposit in the amyloidosis of the Abyssinian cat
and Shar Pei dog is primarily a renal deposit, clinical signs
associated with disrupted renal function will be seen in
the aﬀected Abyssinian cats and Shar Pei dogs, whereas
clinical signs associated with derailed hepatic function may
be manifested in Siamese cats. Deposition of amyloid in
the pancreas of cats, nonhuman primates (macaques and
baboons), and humans can lead to the development of type
2 diabetes mellitus [16, 61]. Amyloid deposition can also
occur in the cortex of the adrenal gland; however, it is not
associated with any functional deﬁciencies [16].
Reactive systemic amyloidosis secondary to chronic
inﬂammatory conditions is often the most severe of the
systemic forms. Liver, kidneys, spleen, lymph nodes, and
adrenal glands are most commonly aﬀected. Animals with
renal amyloidosis frequently die from renal failure [16].
The clinical sign usually reﬂects the functional disruption
and severity of the particular site of the kidney aﬀected in
renal amyloidosis. Progressive renal failure was the cause of
death in Dorcas gazelles with renal medullary amyloidosis
[35]. In contrast, although renal medullary amyloidosis6 Veterinary Medicine International
occurs in most cases of bovine renal amyloidosis, it is a
subclinical disease less hazardous to renal function and
thus less important in clinical disease than glomerular
deposition [78]. In Dorcas gazelle impairment of the renal
function involved obstruction of the medullary tubules
and collecting ducts, leading to atrophy and eventual loss
of nephrons, with progressive interstitial ﬁbrosis in the
medulla and cortex [35]. Interstitial amyloidosis may also
contribute to loss of concentrating ability and renal failure
by interfering directly with maintenance of the medullary
interstitial concentration gradient necessary for reabsorptive
function in the renal tubules [38]. In 74% of the cheetahs
with systemic amyloidosis associated with chronic gastritis,
renal failure was determined to be the sole or partial cause of
death [38]. Clinical signs including rapid weight loss, muscle
atrophy, soft unformed stool, and ventral edema were noted
in a case of a horse gelding with AL amyloidosis associated
with multiple myeloma [17].
7. Grossand Microscopic Lesions
Several diﬀerent pathologic mechanisms and conditions
underlie various forms and types of amyloidosis although
abnormal proteins with similar staining characteristics are
deposited in various organs and tissues of the aﬀected ani-
mals. The gross feature of amyloidosis due to the deposited
amyloid in these tissues and organs is not speciﬁc for
amyloid. The aﬀected organs are often enlarged, moderately
ﬁrm, and abnormally discolored [16]. In AA-amyloidosis,
the deposition in most species is in the central organs
and tissues such as spleen, liver, kidney, and the arterial
walls [20, 79]. Experimentally induced AA Amyloidosis in
sheep principally aﬀected the gastrointestinal tract [80],
and scattered amyloid deposits without clinical diabetes are
usually observed in feline pancreas in increasing age [81].
Depending on the extent of the deposition, there may be
splenomegaly,hepatomegaly,andrenomegalyasspleen,liver,
and kidneys are the most commonly aﬀected organs in
systemic AA-amyloidosis.
Microscopic ﬁndings of the deposition of amyloid pro-
tein may correspond to the grossly visible lesions, or it may
be seen only after microscopic examination without distinct
grossly discernible lesions. Amyloid should be diﬀerentiated
from other similar-appearing extracellular deposits such
as collagen and ﬁbrin [16]. For a ﬁbrillary protein to be
considered amyloidogenic it should produce extracellular
deposits with aﬃnity for the Congo red dye and a green
birefringence under polarized light (Figure 1).
Congo red stain, which does not have chemical speci-
ﬁcity for amyloid, but is dependent on the conformational
property of being arranged in beta-pleated sheets, is the
most commonly used stain for the identiﬁcation of amyloid.
Amyloid stains orange to red under light microscopy, which
appear as an apple-green birefringent material under polar-
ized light [6, 16]. Immunohistochemistry can also be used
not only to identify amyloid deposits but also to identify the
speciﬁcconstituentscomposingthedepositssuchastheanti-
β-light chain antibodies [16]. AA- and AL-amyloid deposits
stain similar with Congo red stain. The identiﬁcation of
AA is usually based on its reactivity with speciﬁc anti-AA
antibodiesandsensitivitytopermanganatepretreatment[82,
83]. The common ultrastructure of amyloid proteins is made
of some nonbranching, rigid ﬁbrils, 7.5 to 10nm wide, and
of variable length, which arrange themselves in antiparallel
sheets with β structure [75].
Microscopically, amyloid is deposited extracellularly in
various aﬀected tissues. The involved tissues and organs
vary in diﬀerent animal species and types and forms of
amyloidosis. Amyloid deposition was seen in the kidneys,
blood vessels, spleen, liver, lymph nodes, gastrointestinal
tract, and adrenal glands of sheep and goats with AA amyloi-
dosis [6]. There was widening of the medullary interstitium
by eosinophilic homogeneous material, which encroached
upon medullary tubules and collecting ducts with occasional
renal papillary necrosis in Dorcas gazelle with medullary
amyloidosis. The amyloid deposition signiﬁcantly correlated
with interstitial ﬁbrosis, and tubular dilation and atrophy
[35].
In a horse with AL-amyloidosis associated with multiple
myeloma, diﬀu s es e v e r ee x t r a c e l l u l a ra m y l o i dd e p o s i t sw e r e
present in the lamina propria of glandular stomach, duo-
denum, and jejunum. Much of the spleen and sternal bone
marrowwerereplacedbyneoplasticroundcells,andmultiple
foci of amyloid were also present in the spleen and bone
marrow. No signiﬁcant microscopic changes were noted in
the kidneys, liver, and lungs [17]. In a cow with systemic
AL-amyloidosis associated with bovine leukocyte adhesion
deﬁciency, amyloid deposits immunohistochemically related
to immunoglobulin kappa-light chains of precursor protein
were present in the perivascular and intercellular spaces
of the visceral organs, such as the liver, kidneys, pancreas,
adrenal glands, and upper alimentary tract [51].
8. Infectivityof PrionDiseases and
Amyloid Proteins
Proteins are a major constituent of cells with speciﬁc biolog-
ical functions. Besides the primary structure of the sequence
of amino acids that comprise a protein, the secondary
structure represents the ﬁrst step of folding, deﬁning the
general conformation of proteins. The biological functions
of proteins are directly dependent on the acquisition of
their conformation [84]. Protein misfolding, which is central
to the pathogenesis of several neurodegenerative disorders
[85], is caused by deposition of misfolded proteins (prions).
Prion diseases are protein misfolding disorders in which
misfoldingofahost-encodedprionprotein(PrP)occurs.PrP
may exist as a normal cellular prion protein designated as
PrPC and a pathogenic misfolded conformer designated as
PrPSc. The pathogenesis of prion diseases is associated with
the accumulation of the aggregates of misfolded conformers
(PrPSc) [86]. PrPSc are infectious, naturally transmissible
misfoldedproteinswithneurotoxicpropertiesandcausefatal
neurological diseases in humans and wide range of animal
species [85–87].Veterinary Medicine International 7
Figure 1: Histological features of skin of a dog with nodular cutaneous amyloidosis, which stained light eosinophilic with haematoxylin-
eosin (A) and red with Congo red stain (B). The amyloid showed yellow-green birefringence (C) illuminated with polarized light,
characteristic of amyloid deposits.
Sixteen diﬀerent variants of prion disease have been
identiﬁed in humans and animals [86]. Animal prion dis-
eases include scrapie of sheep and goats, bovine spongiform
encephalopathy (BSE) or mad cow disease, transmissible
mink encephalopathy, feline spongiform encephalopathy,
exotic ungulate spongiform encephalopathy, chronic wast-
ing disease of cervids, and spongiform encephalopathy of
primates [86]. In humans, prion diseases are traditionally
classiﬁed into Creutzfeldt-Jakob disease (CJD), its variant
form (vCJD) resulting from human infection by BSE pri-
ons, Gerstmann-Str¨ aussler-Scheinker disease (GSS) and fatal
familial insomnia (FFI) [85].
Prion diseases can arise without any apparent cause
as in sporadic Creutzfeldt-Jakob disease (CJD) or due to
genetic disorders linked to mutations in the endogenous
PrP protein. The diseases can also be acquired by infection,
through ingestion of contaminated products or through
iatrogenic procedures and are in most cases experimentally
transmissible [86]. Infectivity and transmissibility of prion
disease has been much of a concern particularly since the
outbreak of BSE in cattle. Cattle are infected with BSE
when they ingest prion-contaminated meat and bone meal
of ruminant origin contaminated with prions. Consumption
of BSE-contaminated bovine tissues is associated with a
fatal variant form of Creutzfeldt-Jakob disease (vCJD) in
humans [87, 88]. The variant form of Creutzfeldt-Jakob
disease can also be transmitted from humans to humans
by blood transfusion [89]. Transmission of sheep scrapie
agent through secretion of prions into milk from ewe with
scrapie and lentiviral mastitis is reported to infect 90% of
na¨ ıve suckling lambs [90]. Goats can be infected by contact
with scrapie-infected sheep, either directly or by exposure to
contaminated pastures [87].
Prion diseases and amyloidosis present many similar
aspects of the so-called conformational diseases, accord-
ing to the interpretation which prion infections could be
considered as a form of transmissible cerebral amyloidosis.
This emerging concept of prion infections as a form of
transmissible cerebral amyloidosis is an application of the
prions’ transmissibility concept to a broader spectrum of
amyloid. Amyloid ﬁbers show an extremely high content
of β-sheet, in a very similar structure to the one observed
among prion rods, associated to the transmissible spongi-
formencephalopathies.AmyloiddiseasessuchasAlzheimer’s
and Parkinson’s disease are “infectious” in the sense that
misfolded β-sheeted conformers formed in a nucleation
process in which preformed metastable oligomer acts as a
seed to convert a normal isoform into an abnormal protein
with a misfolded conformation [84]. Although only prion
infections have a proven infectivity in a microbiological
sense [84], Lundmark et al. [14] detected the transmissibility
of systemic amyloidosis by a prion-like mechanism among
mice. This transmissibility of systemic amyloidosis by a
prion-like mechanism in a very eﬀective way provided
evidence that some forms of amyloidosis are transmissible
diseases, similar to the prion-associated disorders [14].
As described earlier, prions in diﬀerent types of trans-
missible spongiform encephalopathies and amyloidosis are
demonstrated to be naturally and experimentally transmissi-
ble. Furthermore, prions are reported to be more resistant
than endospores to standard inactivation methods such
as heat, irradiation, and chemicals [88]. This necessitates
establishing reliable diagnostic procedures to avoid trans-
mission of prion proteins from animals to humans through
consumption of infected or contaminated animal products.
Some eﬀorts are made to develop rapid detection of
abnormal proteins in animal tissues. SAA level was shown to
increaseincowswithpathologicalconditionsascomparedto
healthy cattle. Although it did not reveal a clear association
between acute phase proteins levels and respective speciﬁc
pathological conditions, determination of the serumlevels of
the acute phase proteins such as SAA could be a useful tool
enabling separation of “suspect” from “nonsuspect” animals
before transport to slaughter or during antemortem inspec-
tion in meat inspection systems [91]. However, because high
blood levels of the acute phase proteins are temporary, can8 Veterinary Medicine International
be associated with various conditions, may subside later, and
lackstandardization,acutephaseproteinanalysisaloneisnot
reliable and should be used in association with other tools of
inspection [91]. Therefore, it is necessary to develop other
rapid and accurate method of antemortem or post-mortem
diagnosis of abnormal proteins, as part of meat inspection
procedure. In Japan, PCR identiﬁcation of species-speciﬁc,
animal group-speciﬁc, and plant DNA is employed as part of
feed ban in place for the control of BSE. The PCR method
is of fundamental importance for the detection of prohibited
animal-derived material in feed [92] and could be employed
as part of inspection of meat and other products of animal
origin intended for human consumption.
9. Conclusion
In summary, the pathology and clinical ﬁndings of amyloi-
dosis in animals are diverse depending upon the underlying
causes and species aﬀected. The functional derangement of
the tissues and organs involved and the extent of functional
disruption of the aﬀected organs in various animal species
as well as concurrent infections inﬂuence the various clinical
presentations seen in animals with amyloidosis.
Microscopic examination and Congo red staining with
green birefringence under polarized light are required to
conﬁrm deposition of amyloid substance and thereby rule
out similar extracellular deposits such as collagen and
ﬁbrin. Although this is used as a diagnostic criteria for
amyloid deposits, identifying the type of amyloid deposited,
diﬀerentiating local from systemic (primary or secondary),
or inherited familial deposits from acquired conditions,
would be important for clinical management of the patient.
Therefore, apart from conﬁrmation of amyloid with Congo
redstain,classiﬁcationusingimmunohistochemicalstaining,
ultrastructural characterization of the amyloid ﬁbril, and if
feasible genetic studies of the involved species should be
considered for clinical and prognostic purposes.
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